Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Cash from Operations (2016 - 2017)

Bone Biologics (BBLG) has disclosed Cash from Operations for 2 consecutive years, with 931700.0 as the latest value for Q4 2017.

  • On a quarterly basis, Cash from Operations rose 26.51% to 931700.0 in Q4 2017 year-over-year; TTM through Dec 2017 was 3330096.0, a 54.56% increase, with the full-year FY2025 number at 2691150.0, up 34.76% from a year prior.
  • Cash from Operations was 931700.0 for Q4 2017 at Bone Biologics, down from 561035.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 561035.0 in Q3 2017 to a low of 2527032.0 in Q1 2016.